drugset
drugset / Trial / NCT02714569

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

NCT02714569 ↗

Phase 1 Completed 60 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.

Timeline

Start
2016-03
Primary completion
2017-02-15
Completion
2017-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3202328 Unknown 1 mg Oral
Subject LY3202328 Unknown 3 mg Oral
Subject LY3202328 Unknown 5 mg Oral
Subject LY3202328 Unknown 10 mg Oral
Subject LY3202328 Unknown 20 mg Oral
Subject LY3202328 Unknown 30 mg Oral
Subject LY3202328 Unknown 100 mg Oral
Subject LY3202328 Unknown 300 mg Oral
Subject LY3202328 Unknown 600 mg Oral
Background Atorvastatin Small molecule 10 mg Oral
Background Simvastatin Small molecule 10 mg Oral

Indications

hyperlipidemia